

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The 6-month results of the OPTYX multicenter registry of patients with advanced prostate cancer who received regulogix demonstrated which of the following results?**
 - Cardiovascular adverse effects were a common occurrence
 - Rates of discontinuation were low**
 - Adverse events were worsened with regulogix as monotherapy versus in combination with other agents
- 2. The EMBARK trial evaluating enzalutamide as monotherapy or in combination with leuprolide for patients with biochemical recurrence after definitive local therapy reported which of the following efficacy outcomes?**
 - No improvement in metastasis-free survival (MFS)
 - A numerical but nonsignificant improvement in MFS
 - A significant improvement in MFS**
- 3. The Phase III CAPitello-281 study of capivasertib versus placebo in combination with abiraterone/prednisone and androgen deprivation therapy for patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer reported which of the following efficacy outcomes?**
 - No improvement in radiographic progression-free survival (rPFS) or in overall survival (OS) with the capivasertib combination
 - Significant improvement in rPFS but no improvement in OS with the capivasertib combination
 - Significant improvement in rPFS and a trend toward improved OS with the capivasertib combination**
- 4. The combination of talazoparib/enzalutamide demonstrated an OS advantage in which of the following cohorts of patients with metastatic castration-resistant prostate cancer (mCRPC) in the Phase III TALAPRO-2 trial?**
 - Patients with homologous recombination repair gene mutations
 - All-comers
 - Both a and b**
 - Neither a nor b
- 5. In the Phase III PROpel study of olaparib with abiraterone versus abiraterone alone for mCRPC, which of the following statements is true regarding patients with a germline or somatic BRCA mutation?**
 - No significant improvement in rPFS or OS in the all-comer population
 - A significant improvement in rPFS but not in OS in the all-comer population**
 - A significant improvement in both rPFS and OS in the all-comer population